{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schnabel RB"],"funding":["Bristol Myers Squibb-Pfizer Alliance","German Research Foundation","German Ministry of Education and Research, Berlin, Germany","Union's Horizon 2020 research and innovation programme","Canadian Institutes of HealthResearch","BMBF","German Ministry of Research and Education","Daiichi Sankyo Europe","Accelerating Clinical Trials Network","Population Health Research Institute","ERACoSysMed3","Leducq Foundation","Dutch Heart Foundation","European Union's Horizon Europe research and innovation programme","AFFECT EU","British Heart Foundation","Medtronic","Hamilton Health Sciences","Wolfgang Seefried project funding German Heart Foundation","Heart and Stroke Foundation of Canada","European Union CATCH ME","German Centre for Cardiovascular Research","German Centre for Cardiovascular Research, Berlin, Germany","European Union's Horizon 2020 research and innovation programme","MAESTRIA","Canadian Stroke Prevention Intervention Network"],"pagination":["4902-4916"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11631065"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["45(46)"],"pubmed_abstract":["<h4>Background and aims</h4>The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.<h4>Methods</h4>These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and deat"],"journal":["European heart journal"],"pubmed_title":["Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials."],"pmcid":["PMC11631065"],"funding_grant_id":["847770","633196","FKZ 81X2800182","101095480","201610PTJ-378238","Ki 509167694","BMBF 01ZX1408A","648131","01-002-2022-0118","965286","031L0239","AA/18/2/34218"],"pubmed_authors":["Schnabel RB","Zapf A","Marijon E","Vardas P","Healey JS","Erath JW","Simantirakis E","Schotten U","Kutyifa V","Camm AJ","Atar D","Sehner S","Rivard L","Linde C","Becher N","Lopes RD","Benezet-Mazuecos J","Mabo P","Chlouverakis G","Dichtl W","Toennis T","Lee SF","Blomstrom-Lundqvist C","Lip GYH","Bertaglia E","McIntyre WF","Fierenz A","Goette A","Alings M","Birnie DH","Benz AP","Kirchhof P","Granger CB"],"additional_accession":[]},"is_claimable":false,"name":"Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials.","description":"<h4>Background and aims</h4>The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation.<h4>Methods</h4>These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and deat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-26T23:12:51.811Z","creation":"2025-04-06T17:30:55.59Z"},"accession":"S-EPMC11631065","cross_references":{"pubmed":["39222018"],"doi":["10.1093/eurheartj/ehae596"]}}